View source for Elotuzumab

__NOTOC__
{{SI}}
{{CMG}}

==Overview==
'''Elotuzumab''' (brand name '''Empliciti''', previously known as '''HuLuc63''') is a [[humanized monoclonal antibody]] used in relapsed [[multiple myeloma]].<ref name=FDA>{{cite web|title=Press Announcement—FDA approves Empliciti, a new immune-stimulating therapy to treat multiple myeloma|url=http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm474684.htm|website=U.S. Food and Drug Administration|accessdate=3 December 2015}}</ref>  The package insert denotes its mechanism as a [[SLAMF7]]-directed (also known as CD 319) immunostimulatory antibody.<ref name=PI>{{cite web|title=Empliciti (elotuzumab) for Injection, for Intravenous Use. Full Prescribing Information|url=http://packageinserts.bms.com/pi/pi_empliciti.pdf|website=Empliciti (elotuzumab) for US Healthcare Professionals|publisher=Bristol-Myers Squibb Company, Princeton, NJ 08543 USA}}</ref>
==Approvals and indications==
===Multiple myeloma===
In May 2014, it was granted "[[Breakthrough Therapy]]" designation by the [[Food and Drug Administration|FDA]] (for multiple myeloma). <ref>{{cite press release |url=http://news.bms.com/press-release/rd-news/bristol-myers-squibb-and-abbvie-receive-us-fda-breakthrough-therapy-designatio |title=Bristol-Myers Squibb and AbbVie Receive U.S. FDA Breakthrough Therapy Designation for Elotuzumab, an Investigational Humanized Monoclonal Antibody for Multiple Myeloma |location=Princeton, NJ & North Chicago, IL |date=2014-05-19 |accessdate=2015-02-05 |publisher=Bristol-Myers Squibb}}</ref> On November 30, 2015, FDA approved elotuzumab as a treatment for patients with multiple myeloma who have received one to three prior medications.<ref name=FDA/> Elotuzumab was labeled for use with [[lenalidomide]] and [[dexamethasone]]. Each intravenous injection of elotuzumab should be premedicated with dexamethasone, [[diphenhydramine]], [[ranitidine]] and [[acetaminophen]].<ref name=PI/> In May 2016 the EC/EU gave a similar approval.<ref>[http://www.pmlive.com/pharma_news/bms_gets_two_new_cancer_approvals_in_europe_1021270 BMS gets two new cancer approvals in Europe. May 2016]</ref>

==References==
{{Reflist}}

==External links==
* [http://www.empliciti.com Empliciti (elotuzumab) Official Web Site]

{{Monoclonals for tumors}}

[[Category:Monoclonal antibodies for tumors]]
[[Category:Breakthrough therapy]]

{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}